Over 50% of adults globally report having at least one pigmentary disorder, according to the Journal of Investigative Dermatology. Hyperpigmentation, including sunspots and melasma, remains one of skincare’s most persistent concerns, driving demand for ingredients that visibly reduce discoloration without irritating the skin.
Biotechnology company Debut, known for using artificial intelligence to develop beauty ingredients, has engineered a new biotech active for hyperpigmentation as regulators increase scrutiny of established ingredients like kojic acid, which has long been used to address hyperpigmentation.
In April 2024, the European Commission introduced a significant cosmetic regulatory update around kojic acid. Effective February 2025, face and hand products sold in the EU can contain a maximum concentration of 1% kojic acid. The restriction followed safety concerns including potential endocrine-disrupting properties and dermal absorption. In higher concentrations, the ingredient can cause irritation or allergic contact dermatitis.
“For decades, the treatment of hyperpigmentation has forced a trade-off: potent enough to work, or gentle enough to use,” said Joshua Britton, PhD, Founder and CEO of Debut, in a press release.
Called DermCeutical PNar, the new biotech active is designed to correct hyperpigmentation and brighten the skin at a 0.45% use level without the use of kojic acid. PNar is a next-generation tyrosinase inhibitor, targeting enzymes involved in melanin production. According to Debut, the molecule was developed by identifying the biological drivers of hyperpigmentation and engineering new molecules around those targets.
The ingredient is designed to reduce melanin production before dark spots appear, while helping address hyperpigmentation and uneven skin tone across skin tones, per company claims. With a lower concentration of actives, Debut is focusing on precision rather than increasing the percentage of an existing active.
“The challenge was to engineer a molecule that could deliver superior performance at a low use level, while driving skin longevity,” continued Britton. “PNar demonstrates what’s possible when you start with biology, identify the precise target, and then design the molecule.”
The launch reflects a broader shift in beauty ingredient development toward biotech and precision-engineered actives. As regulators continue to scrutinize the safety of highly concentrated actives, brands are forced to find new alternatives.